Search

Objective: To analyze the relationship between ceruloplasmin（CER）, squamous cell carcinoma associated antigen（SCCA） and chronic renal failure（CRF） and their predictive value for disease progression. Methods: A total of 169 patients with chronic renal failure admitted to our hospital from April 2019 to April 2021 were selected as the study subjects. According to 12 h urinary albumin quantification,the patients were divided into microalbuminuria group（＜200 mg/24 h, 102 cases） and macroalbuminuria group（＞200 mg/24 h, 67 cases）. The laboratory indexes and serum CER and SCCA levels of the two groups were compared, and the relationship between CER, SCCA and renal function indexes of patients with chronic renal failure was analyzed. Patients were followed up for 24 months to observe the progression of the disease. Area under receiver operating Characteristic Curve（AUC） was used to evaluate the predictive efficacy of CER combined with SCCA on the progression of the disease. Results: The levels of serum creatinine（Scr） and blood urea nitrogen（BUN） in moderate proteinuria group were higher than those in mild proteinuria group, and the glomerular filtration rate（GFR） was lower than that in mild proteinuria group（P＜0.05）. The levels of CER and SCCA in moderate proteinuria group were higher than those in mild proteinuria group（P＜0.05）. Pearson correlation analysis showed that CER and SCCA levels were positively correlated with Scr and BUN, but negatively correlated with GFR（P＜0.05）. Multivariate Logistic regression analysis showed that GFR,CER and SCCA were independent predictors of chronic renal failure（P＜0.05）. According to ROC curve analysis, the AUC of CER combined with SCCA in predicting the progression of chronic renal failure was 0.926,which was significantly higher than 0.683 of GFR（P＜0.05）. Conclusion: The levels of CER and SCCA are negatively correlated with renal function in patients with chronic renal failure. The combined efficacy of CER and SCCA in predicting the progression of patients’ disease is good and worthy of clinical attention. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)